Interleukin-17A inhibitors (IL-17Ai) have become a first-line option for axial spondyloarthritis (axSpA) patients unresponsive to NSAIDs, alongside tumor necrosis factor inhibitors, per ASAS-EULAR guidelines. Real-world evidence remains limited.
The ESPADA study, a retrospective observational study in Spain, evaluated ixekizumab (IXE) in routine practice. Most patients had long-standing, active axSpA with prior biologic treatment, yet over half maintained IXE treatment at one year, supporting its use as a viable therapy.